CIRM
Senti Bio Receives $8M Grant to Advance CAR-NK Therapy in Certain Blood Cancers
The firm will use the funds to support an ongoing Phase I trial of SENTI-202 in CD33- and FLT3-expressing hematologic malignancies.
FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies
In a draft guidance, the agency outlined how the well-understood and reproducible components of genetic medicines could qualify as platform technologies.
Denovo Biopharma, Anova Get $11.8M Grant to Study Biomarker-Guided Gene Therapy in Glioma Patients
Denovo, Anova, and academic partners will put the funds toward studying DB107 in certain gliomas.